Kimberly Blackwell MD
Dr. Blackwell is the co-founder of Cereius and the Vice President, Early Phase Development at Eli Lilly and Company. She is a board certified medical oncologist, having trained at Mayo Clinic Medical School and Duke University Medical Center. For over 20 years, she was a Professor and breast medical oncologist at Duke Cancer Center, holding a variety of positions including Director of the Breast Cancer Program and the Women’s Cancer Program. Prior to becoming an adjunct professor in 2018, she was the co-director of the Duke Center for Solid Tumor Brain Metastasis and the director of Strategic Relations for the Duke Cancer Institute. Today she serves to oversee all early phase Oncology and Immuno-oncology development at Eli Lilly and Company.
Dr. Blackwell contributed significantly to the development of a number of breast cancer therapeutics, in particular, agents directed at HER2+ breast cancer. She served as the principle investigator on several studies that led to the approval of HER2 targeted agents, lapatinib and T-DM1. She has been the author of over 100 peer-reviewed publication and is considered a thought leader in the field of breast cancer. She serves or has served on multiple biotech boards for companies focused on oncology. Dr. Blackwell is the recipient of numerous awards, most notably the Duke University Alumni of the Year and the TIME 100 Most Influential People in the World.